We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
-20.94%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$322M
AUM Growth
-$149M
(-32%)
Cap. Flow
-$24.6M
Cap. Flow
% of AUM
-7.63%
Top 10 Holdings %
Top 10 Hldgs %
58.84%
Holding
48
New
9
Increased
13
Reduced
15
Closed
3
Avg Time Held
6.2
quarters
Top 10 Avg Time Held
5.2
quarters
Top 20 Avg Time Held
6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bicycle Therapeutics
BCYC
|
+$8.17M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$3.9M |
| 3 |
Mersana Therapeutics
MRSN
|
+$3.32M |
| 4 |
ProQR Therapeutics
PRQR
|
+$3.31M |
| 5 |
908 Devices
MASS
|
+$2.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$20.7M |
| 2 |
Semler Scientific
SMLR
|
+$6.84M |
| 3 |
Cytokinetics
CYTK
|
+$6.16M |
| 4 |
Sutro Biopharma
STRO
|
+$5.61M |
| 5 |
BridgeBio Pharma
BBIO
|
+$5.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$1.64B
| $29.6M | 9.18% |
5,974,800
| – | – |
2019 Q1
12 quarters
|
|
2
Codexis
CDXS
$153M
| $27.7M | 8.61% |
1,345,000
| – | – |
2014 Q1
32 quarters
|
|
3
DELISTED
Chimerix, Inc.
CMRX
| $27M | 8.4% |
5,903,450
+323,450
| +6% | +$1.8M |
2020 Q2
7 quarters
|
|
4
Harrow
HROW
$1.07B
| $22.4M | 6.97% |
3,291,343
+6,343
| +0.2% | +$49K |
2018 Q3
14 quarters
|
|
5
DELISTED
Crinetics Pharmaceuticals
CRNX
| $15.2M | 4.72% |
693,000
-31,400
| -4% | -$636K |
2021 Q1
4 quarters
|
|
|
6
Cytokinetics
CYTK
$8.67B
| $15M | 4.65% |
406,500
-173,500
| -30% | -$6.16M |
2020 Q2
7 quarters
|
|
7
Keros Therapeutics
KROS
$225M
| $14.5M | 4.49% |
265,750
| – | – |
2021 Q1
4 quarters
|
|
8
Protara Therapeutics
TARA
$160M
| $13.7M | 4.24% |
2,674,031
+24,031
| +0.9% | +$126K |
2019 Q3
10 quarters
|
|
|
RETA
9
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $13.3M | 4.14% |
407,002
+77,002
| +23% | +$2.28M |
2021 Q4
1 quarter
|
|
10
Kiniksa Pharmaceuticals
KNSA
$6.16B
| $11.1M | 3.43% |
1,112,500
+87,500
| +9% | +$927K |
2020 Q2
7 quarters
|
|
11
Eton Pharmaceutcials
ETON
$1.57B
| $10.4M | 3.22% |
2,379,275
-5,725
| -0.2% | -$22.5K |
2018 Q4
13 quarters
|
|
12
DELISTED
Merus
MRUS
| $8.94M | 2.78% |
338,000
+20,200
| +6% | +$541K |
2021 Q3
2 quarters
|
|
13
Stereotaxis
STXS
$109M
| $8.94M | 2.78% |
2,395,600
-130,900
| -5% | -$618K |
2019 Q3
10 quarters
|
|
|
TCON
14
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $8.3M | 2.58% |
157,755
+5,005
| +3% | +$252K |
2020 Q3
6 quarters
|
|
|
15
Bicycle Therapeutics
BCYC
$255M
| $7.68M | 2.38% |
+175,000
| New | +$8.17M |
2022 Q1
0 quarters
|
|
16
DELISTED
Xoma
XOMA
| $7.58M | 2.36% |
271,000
-67,350
| -20% | -$1.54M |
2017 Q1
20 quarters
|
|
|
17
Celldex Therapeutics
CLDX
$2.23B
| $6.66M | 2.07% |
195,500
-648,500
| -77% | -$20.7M |
2020 Q2
7 quarters
|
|
18
Protagonist Therapeutics
PTGX
$9.1B
| $5.96M | 1.85% |
251,500
-90,500
| -26% | -$2.55M |
2020 Q4
5 quarters
|
|
19
TELA Bio
TELA
$48.3M
| $5.55M | 1.72% |
477,000
+27,133
| +6% | +$328K |
2019 Q4
9 quarters
|
|
20
Fortress Biotech
FBIO
$67.4M
| $5.1M | 1.58% |
250,000
| – | – |
2020 Q2
7 quarters
|
|
21
Vaxcyte
PCVX
$10.7B
| $5.1M | 1.58% |
211,000
-104,800
| -33% | -$2.29M |
2020 Q3
6 quarters
|
|
22
4D Molecular Therapeutics
FDMT
$690M
| $4.91M | 1.53% |
325,000
+96,000
| +42% | +$1.51M |
2021 Q4
1 quarter
|
|
23
Larimar Therapeutics
LRMR
$238M
| $3.82M | 1.19% |
943,702
+60,100
| +7% | +$393K |
2021 Q2
3 quarters
|
|
24
Ginkgo Bioworks
DNA
$818M
| $3.75M | 1.16% |
23,245
| – | – |
2021 Q4
1 quarter
|
|
|
25
DELISTED
Semler Scientific
SMLR
| $3.47M | 1.08% |
70,000
-102,000
| -59% | -$6.84M |
2021 Q3
2 quarters
|
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q1 2022 Portfolio in Review
As of Q1 2022, Opaleye Management held 48 positions worth $322M, down 32% from $471M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Opaleye Management withdrew a net $24.6M in Q1 2022, closing 3 positions and reducing 15 holdings. Its most notable exit was BridgeBio Pharma, an estimated $5.47M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Opaleye Management opened a new position in Bicycle Therapeutics worth $7.68M.
- Opaleye Management's largest Q1 2022 buy was Bicycle Therapeutics: 175,000 shares worth $7.68M.
- Opaleye Management added most to ProQR Therapeutics in Q1 2022, an estimated $3.31M increase.
- Opaleye Management's biggest Q1 2022 reduction was Celldex Therapeutics, cutting an estimated $20.7M.
- Opaleye Management fully exited BridgeBio Pharma in Q1 2022, selling an estimated $5.47M.
- Opaleye Management's ten largest holdings make up 59% of its $322M portfolio in Q1 2022.
- Opaleye Management opened 9 new positions and closed 3 in Q1 2022.
- Opaleye Management's portfolio value fell 32% quarter-over-quarter to $322M.
Based on Opaleye Management's 13F filing for Q1 2022, filed 16 May 2022.